Skip to main content
Log in

Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes

  • Original Contributions
  • Published:
Acta diabetologia latina Aims and scope Submit manuscript

Summary

The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Barnett A. H., Gonzalez-Auvert C., Pyke D. A., Saunders J. B., Williams R., Dickenson C. J., Rawlins M. D.: Blood concentrations of acetaldehyde during chlorpropamide-alcohol flush — Brit. med. J.ii, 939, 1981.

    Article  Google Scholar 

  2. De Silva N. E., Tunbridge W. M. G., Alberti K. G. M. M.: Low incidence of chlorpropamide-alcohol flushing in diet-treated, non-insulin-dependent diabetes — Lanceti, 128, 1981.

    Google Scholar 

  3. Editorial: Bromocriptine, a changing scene — Brit. med. J.iv, 667, 1975.

  4. FitzGerald M. G., Gaddie R., Malins J. M., O’Sullivan D. J.: Alcohol sensitivity in diabetics receiving chlorpropamide — Diabetes11, 40, 1962.

    PubMed  CAS  Google Scholar 

  5. Fuxe K., Agnati L., Everitt B.: Effects of metergoline on central monoamine neurons. Evidence for a selective blockade of central 5-HT receptors — Neurosci. Letters1, 283, 1975.

    Article  CAS  Google Scholar 

  6. Köbberling J., Bengsch N., Brüggeboes B., Schwarck H., Tillil H., Weber M.: The chlorpropamide-alcohol flush. Lack of specificity for familial non-insulin dependent diabetes — Diabetologia19, 359, 1980.

    Article  PubMed  Google Scholar 

  7. Leslie R. D. G., Pyke D. A.: Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes — Brit. med. J.ii, 1519, 1978.

    Article  Google Scholar 

  8. Leslie R. D. G., Pyke D. A., Stubbs W. A.: Sensitivity to enkephalin as a cause of non-insulin dependent diabetes — Lanceti, 341, 1979.

    Article  Google Scholar 

  9. Medbak S., Wass J. A. H., Clement-Jones V., Cooke E. D., Bowcook S. A., Cudworth A. G., Rees L. H.: Chlorpropamide alcohol flush and circulating met-enkephalin: a positive link — Brit. med. J.283, 937, 1981.

    Article  CAS  Google Scholar 

  10. Podgainy H., Bressler R.: Biochemical basis of the sulfonylurea induced antabuse syndrome — Diabetes17, 679, 1968.

    PubMed  CAS  Google Scholar 

  11. Pyke D. A.: Diabetes: the genetic connections — Diabetologia17, 333, 1979.

    Article  PubMed  CAS  Google Scholar 

  12. Strakosch C. R., Jefferys D. B., Keen H.: Blockade of chlorpropamide alcohol flush by aspirin — Lanceti, 394, 1980.

    Article  Google Scholar 

  13. Sved S., McGilveray I. J., Beaudoin S.: Assay of sulfonylurea in human plasma by high-performance liquid chromatography — J. pharm. Sci.65, 1356, 1976.

    Article  PubMed  CAS  Google Scholar 

  14. Taylor J. A.: Pharmacokinetics and biotransformation of chlorpropamide in man — Clin. Pharmacol. Ther.13, 710, 1972.

    PubMed  CAS  Google Scholar 

  15. Van Loon G. R., De Souza E. B.: Effects of β-endorphin on brain serotonin metabolism — Life Sci.23, 971, 1978.

    Article  PubMed  Google Scholar 

  16. Van Loon G. R., Ho D., Kim C.: β-endorphin-induced decrease in hypothalamic dopamine turnover — Endocrinology106, 76, 1980.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pontiroli, A.E., De Pasqua, A., Colombo, R. et al. Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes. Acta diabet. lat 20, 116–123 (1983). https://doi.org/10.1007/BF02624912

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02624912

Key-words

Navigation